pSivida to Present at the 2018 BIO CEO & Investor Conference
February 09, 2018 07:00 ET
|
pSivida Corp.
WATERTOWN, Mass., Feb. 09, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced today that Nancy...
pSivida Corp. Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines
February 07, 2018 16:02 ET
|
pSivida Corp.
Newly Released Second Phase 3 Study Data for Durasert Three-Year Treatment for Posterior Segment Uveitis Shows Positive Efficacy and Safety Profile Maintained at 12 Months Awaiting FDA...
pSivida's Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months
February 07, 2018 16:01 ET
|
pSivida Corp.
Highly Significant Difference Between Durasert and Sham in Prevention of Uveitis Recurrence at 12 Months Fiscal Q2 2018 Results Conference Call Scheduled for Today at 4:30 p.m.ET WATERTOWN,...
pSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
January 24, 2018 07:00 ET
|
pSivida Corp.
WATERTOWN, Mass., Jan. 24, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye...
pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA
January 08, 2018 08:30 ET
|
pSivida Corp.
WATERTOWN, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced it has...
pSivida Granted Waiver by the FDA for New Drug Application Filing Fee
January 04, 2018 07:00 ET
|
pSivida Corp.
WATERTOWN, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products, today announced that the U.S. Food...
pSivida to Present at the Annual Biotech Showcase Conference
January 02, 2018 16:01 ET
|
pSivida Corp.
WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products, announced today that Nancy Lurker,...
HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data
December 14, 2017 07:00 ET
|
pSivida Corp.
WATERTOWN, Mass. and NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products, and Hospital for...
pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution
November 07, 2017 06:00 ET
|
pSivida Corp.
NDA Filing for Durasert Three-year Treatment for Posterior Segment Uveitis Remains on Track for Late December 2017/Early January 2018 Conference Call and Webcast Today, November 7th, at 8:30 a.m. ET ...
pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
October 18, 2017 07:00 ET
|
pSivida Corp.
WATERTOWN, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye...